Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Strategies of Combination Drug Delivery for Immune Checkpoint Blockades
Authors
Keywords
-
Journal
Advanced Healthcare Materials
Volume -, Issue -, Pages 1801099
Publisher
Wiley
Online
2018-12-13
DOI
10.1002/adhm.201801099
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Leveraging Engineering of Cells for Drug Delivery
- (2018) Zhaowei Chen et al. ACCOUNTS OF CHEMICAL RESEARCH
- Targeted drug delivery to melanoma
- (2018) Qi Liu et al. ADVANCED DRUG DELIVERY REVIEWS
- A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy
- (2018) Yu Mi et al. ADVANCED MATERIALS
- PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy
- (2018) Xudong Zhang et al. ADVANCED MATERIALS
- Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade
- (2018) Shuangjiang Yu et al. ADVANCED MATERIALS
- A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions
- (2018) Aravindhan Ganesan et al. BMC Medical Informatics and Decision Making
- Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer
- (2018) Lina Liu et al. MOLECULAR THERAPY
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors
- (2018) Tingting Wang et al. Nature Communications
- Nanoscale delivery systems for cancer immunotherapy
- (2018) Zejun Wang et al. Materials Horizons
- Cell-Like Micromotors
- (2018) Berta Esteban-Fernández de Ávila et al. ACCOUNTS OF CHEMICAL RESEARCH
- Engineering PD-1-Presenting Platelets for Cancer Immunotherapy
- (2018) Xudong Zhang et al. NANO LETTERS
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine
- (2017) Xiaojun Shi et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study
- (2017) Jung-Min Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer
- (2017) Amanda Rosewell Shaw et al. MOLECULAR THERAPY
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
- (2017) Daniela Schmid et al. Nature Communications
- Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy
- (2017) Guizhi Zhu et al. Nature Communications
- Cell membrane-coated nanoparticles for tumor-targeted drug delivery
- (2017) Zhilan Chai et al. Science China-Materials
- Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors
- (2016) Yanqi Ye et al. ACS Nano
- Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody
- (2016) Chao Wang et al. ADVANCED MATERIALS
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Designer vaccine nanodiscs for personalized cancer immunotherapy
- (2016) Rui Kuai et al. NATURE MATERIALS
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy
- (2016) Chunbai He et al. Nature Communications
- Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy
- (2016) Qian Chen et al. Nature Communications
- Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
- (2016) Maarten Swart et al. Frontiers in Oncology
- Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis
- (2015) Anne Bertrand et al. BMC Medicine
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
- (2015) Siwen Hu-Lieskovan et al. Science Translational Medicine
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
- (2015) O. A. Ali et al. Cancer Immunology Research
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
- (2015) Paolo A. Ascierto et al. EBioMedicine
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Does the Immune System Naturally Protect Against Cancer?
- (2014) Alexandre Corthay Frontiers in Immunology
- Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
- (2013) Yuan Zhang et al. BIOMATERIALS
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
- (2013) Aurélien Marabelle et al. JOURNAL OF CLINICAL INVESTIGATION
- Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis
- (2013) Zhenghong Xu et al. JOURNAL OF CONTROLLED RELEASE
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- How do CARs work?
- (2012) Marco L. Davila et al. OncoImmunology
- Complement: a key system for immune surveillance and homeostasis
- (2010) Daniel Ricklin et al. NATURE IMMUNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
- (2009) W M Liu et al. BRITISH JOURNAL OF CANCER
- Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy
- (2009) Joseph R. Podojil et al. IMMUNOLOGICAL REVIEWS
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC)
- (2008) Malarvizhi Durai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started